Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.44M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Tempest Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 17 | 21 | +4 |
| Shares | 585.8K | 787.5K | +201.7K (+34.4%) |
| Value | $6.02M | $2.26M | −$3.76M (−62.5%) |
New holders (6)
Institutions that held Tempest Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 178,592 | $512.6K | 4.27% |
| Northern Trust Corp | 14,053 | $40.3K | 0.00% |
| Dimensional Fund Advisors LP | 11,444 | $32.8K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,325 | $3.80K | 0.00% |
| Jones Financial Companies LLLP | 239 | $686 | 0.00% |
| Royal Bank of Canada | 8 | $0 | 0.00% |
Sold out (2)
Institutions that held Tempest Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Belvedere Trading LLC | 5,325 | $54.7K |
| Wells Fargo & Company | 3 | $31 |